Compass Therapeutics, Inc. (NASDAQ:CMPX) Short Interest Update

Compass Therapeutics, Inc. (NASDAQ:CMPX) was the recipient of a significant growth in short interest in the month of February. As of February 15th, there was short interest totalling 3,530,000 shares, a growth of 28.4% from the January 31st total of 2,750,000 shares. Approximately 4.4% of the shares of the stock are short sold. Based on an average trading volume of 1,330,000 shares, the short-interest ratio is presently 2.7 days.

Analyst Ratings Changes

Several brokerages have issued reports on CMPX. Jefferies Financial Group lifted their price objective on Compass Therapeutics from $7.00 to $8.00 and gave the company a “buy” rating in a research report on Monday, February 10th. Piper Sandler initiated coverage on shares of Compass Therapeutics in a report on Wednesday, February 19th. They set an “overweight” rating and a $12.00 target price for the company. D. Boral Capital reaffirmed a “buy” rating and set a $32.00 price target on shares of Compass Therapeutics in a research report on Tuesday, February 25th. HC Wainwright reissued a “buy” rating and set a $10.00 price target on shares of Compass Therapeutics in a research report on Wednesday, January 8th. Finally, Leerink Partners lowered shares of Compass Therapeutics from an “outperform” rating to a “market perform” rating and decreased their price target for the company from $5.00 to $4.00 in a research note on Friday, November 15th. Two analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $11.38.

Institutional Investors Weigh In On Compass Therapeutics

Several hedge funds have recently modified their holdings of CMPX. Barclays PLC lifted its holdings in Compass Therapeutics by 195.4% during the third quarter. Barclays PLC now owns 170,245 shares of the company’s stock valued at $314,000 after purchasing an additional 112,614 shares in the last quarter. SG Americas Securities LLC lifted its stake in Compass Therapeutics by 921.6% in the 4th quarter. SG Americas Securities LLC now owns 395,017 shares of the company’s stock valued at $573,000 after buying an additional 356,352 shares in the last quarter. Geode Capital Management LLC boosted its holdings in Compass Therapeutics by 0.8% in the 3rd quarter. Geode Capital Management LLC now owns 2,309,778 shares of the company’s stock worth $4,251,000 after buying an additional 19,095 shares during the last quarter. Bleakley Financial Group LLC increased its stake in Compass Therapeutics by 250.7% during the 4th quarter. Bleakley Financial Group LLC now owns 39,993 shares of the company’s stock worth $58,000 after buying an additional 28,589 shares in the last quarter. Finally, The Manufacturers Life Insurance Company purchased a new stake in Compass Therapeutics during the 3rd quarter worth approximately $79,000. 68.43% of the stock is owned by hedge funds and other institutional investors.

Compass Therapeutics Trading Down 5.2 %

CMPX stock traded down $0.15 during trading on Thursday, reaching $2.63. The stock had a trading volume of 166,092 shares, compared to its average volume of 643,341. Compass Therapeutics has a 52 week low of $0.77 and a 52 week high of $4.08. The stock’s 50 day moving average is $2.66 and its two-hundred day moving average is $1.98. The firm has a market cap of $361.17 million, a PE ratio of -7.15 and a beta of 1.17.

Compass Therapeutics (NASDAQ:CMPX) last issued its quarterly earnings results on Thursday, February 27th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.01). On average, research analysts anticipate that Compass Therapeutics will post -0.36 EPS for the current year.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.